Global healthcare company to invest in biotech at home
Paris – Sanofi-Aventis has opened its Biolaunch project at the Vitry-sur-Seine pharmaceuticals production site, where it plans to invest EUR200m to develop biotech expertise, including the production of monoclonal antibodies by 2012.
“With Biolaunch, Sanofi-Aventis will benefit from a complete platform of expertise in biotechnologies. Monoclonal antibodies will open the way to a new generation of better-targeted and more effective treatments with fewer side effects,” said CEO Chris Viehbacher at the opening.
“This project, which gathers and mobilises the best expertise both inside and outside the company, is an illustration of the ongoing transforming programme within Sanofi-Aventis,” said Viehbacher.
Biolaunch is part of the company’s long-term approach to investing in biotech, and is a core part of its plan to turn the site into a comprehensive biotechnology campus that includes research, development and production activities. Sanofi-Aventis is also planning to open the facilities to other companies to develop and produce biopharmaceuticals. The Biolaunch project also includes a training programme in biotech business activities.